Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Abstract Antibody-dependent cellular cytotoxicity (ADCC) responses to viral infection are a form of antibody regulated immune responses mediated through the Fc fragment. Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered ADCC responses contributes to COVID-19 disease deve...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-09-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-021-00759-1 |
| _version_ | 1818438351733129216 |
|---|---|
| author | Yuanling Yu Meiyu Wang Xiaoai Zhang Shufen Li Qingbin Lu Haolong Zeng Hongyan Hou Hao Li Mengyi Zhang Fei Jiang Jiajing Wu Ruxia Ding Zehua Zhou Min Liu Weixue Si Tao Zhu Hangwen Li Jie Ma Yuanyuan Gu Guangbiao She Xiaokun Li Yulan Zhang Ke Peng Weijin Huang Wei Liu Youchun Wang |
| author_facet | Yuanling Yu Meiyu Wang Xiaoai Zhang Shufen Li Qingbin Lu Haolong Zeng Hongyan Hou Hao Li Mengyi Zhang Fei Jiang Jiajing Wu Ruxia Ding Zehua Zhou Min Liu Weixue Si Tao Zhu Hangwen Li Jie Ma Yuanyuan Gu Guangbiao She Xiaokun Li Yulan Zhang Ke Peng Weijin Huang Wei Liu Youchun Wang |
| author_sort | Yuanling Yu |
| collection | DOAJ |
| description | Abstract Antibody-dependent cellular cytotoxicity (ADCC) responses to viral infection are a form of antibody regulated immune responses mediated through the Fc fragment. Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered ADCC responses contributes to COVID-19 disease development is currently not well understood. To understand the potential correlation between ADCC responses and COVID-19 disease development, we analyzed the ADCC activity and neutralizing antibody response in 255 individuals ranging from asymptomatic to fatal infections over 1 year post disease. ADCC was elicited by 10 days post-infection, peaked by 11–20 days, and remained detectable until 400 days post-infection. In general, patients with severe disease had higher ADCC activities. Notably, patients who had severe disease and recovered had higher ADCC activities than patients who had severe disease and deceased. Importantly, ADCC activities were mediated by a diversity of epitopes in SARS-COV-2-infected mice and induced to comparable levels against SARS-CoV-2 variants of concern (VOCs) (B.1.1.7, B.1.351, and P.1) as that against the D614G mutant in human patients and vaccinated mice. Our study indicates anti-SARS-CoV-2 ADCC as a major trait of COVID-19 patients with various conditions, which can be applied to estimate the extra-neutralization level against COVID-19, especially lethal COVID-19. |
| first_indexed | 2024-12-14T17:39:11Z |
| format | Article |
| id | doaj.art-f7e279e200ea4eada010dd990ab56046 |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-12-14T17:39:11Z |
| publishDate | 2021-09-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-f7e279e200ea4eada010dd990ab560462022-12-21T22:52:53ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352021-09-016111010.1038/s41392-021-00759-1Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patientsYuanling Yu0Meiyu Wang1Xiaoai Zhang2Shufen Li3Qingbin Lu4Haolong Zeng5Hongyan Hou6Hao Li7Mengyi Zhang8Fei Jiang9Jiajing Wu10Ruxia Ding11Zehua Zhou12Min Liu13Weixue Si14Tao Zhu15Hangwen Li16Jie Ma17Yuanyuan Gu18Guangbiao She19Xiaokun Li20Yulan Zhang21Ke Peng22Weijin Huang23Wei Liu24Youchun Wang25Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of SciencesDepartment of Laboratorial Science and Technology, School of Public Health, Peking UniversityDepartment of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Sinovac Biotech Co., LtdCansino Biotech IncorporationCansino Biotech IncorporationStemirna Therapeutics, LtdStemirna Therapeutics, LtdStemirna Therapeutics, LtdAnhui Zhifeilongcom Biopharmaceutical Co., LtdState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyState Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of SciencesState Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of SciencesDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and EpidemiologyDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)Abstract Antibody-dependent cellular cytotoxicity (ADCC) responses to viral infection are a form of antibody regulated immune responses mediated through the Fc fragment. Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered ADCC responses contributes to COVID-19 disease development is currently not well understood. To understand the potential correlation between ADCC responses and COVID-19 disease development, we analyzed the ADCC activity and neutralizing antibody response in 255 individuals ranging from asymptomatic to fatal infections over 1 year post disease. ADCC was elicited by 10 days post-infection, peaked by 11–20 days, and remained detectable until 400 days post-infection. In general, patients with severe disease had higher ADCC activities. Notably, patients who had severe disease and recovered had higher ADCC activities than patients who had severe disease and deceased. Importantly, ADCC activities were mediated by a diversity of epitopes in SARS-COV-2-infected mice and induced to comparable levels against SARS-CoV-2 variants of concern (VOCs) (B.1.1.7, B.1.351, and P.1) as that against the D614G mutant in human patients and vaccinated mice. Our study indicates anti-SARS-CoV-2 ADCC as a major trait of COVID-19 patients with various conditions, which can be applied to estimate the extra-neutralization level against COVID-19, especially lethal COVID-19.https://doi.org/10.1038/s41392-021-00759-1 |
| spellingShingle | Yuanling Yu Meiyu Wang Xiaoai Zhang Shufen Li Qingbin Lu Haolong Zeng Hongyan Hou Hao Li Mengyi Zhang Fei Jiang Jiajing Wu Ruxia Ding Zehua Zhou Min Liu Weixue Si Tao Zhu Hangwen Li Jie Ma Yuanyuan Gu Guangbiao She Xiaokun Li Yulan Zhang Ke Peng Weijin Huang Wei Liu Youchun Wang Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients Signal Transduction and Targeted Therapy |
| title | Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients |
| title_full | Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients |
| title_fullStr | Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients |
| title_full_unstemmed | Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients |
| title_short | Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients |
| title_sort | antibody dependent cellular cytotoxicity response to sars cov 2 in covid 19 patients |
| url | https://doi.org/10.1038/s41392-021-00759-1 |
| work_keys_str_mv | AT yuanlingyu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT meiyuwang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT xiaoaizhang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT shufenli antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT qingbinlu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT haolongzeng antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT hongyanhou antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT haoli antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT mengyizhang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT feijiang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT jiajingwu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT ruxiading antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT zehuazhou antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT minliu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT weixuesi antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT taozhu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT hangwenli antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT jiema antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT yuanyuangu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT guangbiaoshe antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT xiaokunli antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT yulanzhang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT kepeng antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT weijinhuang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT weiliu antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients AT youchunwang antibodydependentcellularcytotoxicityresponsetosarscov2incovid19patients |